The ability of strains of Bacillus, Staphylococcus, Pseudomonas, and Escherichia coli to inactivate rifampicin was tested. Most Bacillus strains were found to inactivate rifampicin. Twomodesof inactivation were identified; one was phosphorylation and the other involved decolorization. Presence or absence of either mechanismappeared unrelated to the phylogenetic relatedness of strains. None of the other organisms could inactivate this antibiotic. Rifampicin (Fig.
Rifampicin (
) is a semisynthetic derivative of the rifamycin group of antibiotics1 '2) .
These have as their mode of action the inhibition of prokaryotic DNA dependent RNApolymerase5) and the classical mode of resistance has been shownto be mutational alteration of the target moiety, specifically, the /? subunit of this enzyme4).
Rifampicin is one of the principal agents used to combat infections by nocardioform bacteria of the genera Mycobacterium, Nocardia, and Rhodococcus5~n). Our studies in which these organisms were challenged by this compoundrevealed an additional aspect of the interaction, viz. inactivation of the antibiotic. An unexpected variety of mechanisms was found: glucosylation in N. brasiliensis7\ phosphorylation in N. otitidiscaviarum8), nbosylation in Mycobacterium strains ( Fig. 1)9 ), and one involving decomposition in N. asteroides8) and Rhodococcusstrains10 '1 1}. As these were the first reports of rifampicin inactivation we wished to determine if bacteria other than no-815 cardioforms also possessed a similar enzymatic activity. In this paper, we describe the response of strains from several other genera to challenge by this antibiotic.
Materials and Methods Organisms
10 strains of Pseudomonas aeruginosa, 8 strains of Escherichia coli, 4 strains of methicillin-sensitive Staphylococcus aureus (MSSA), and 6 strains of methicillinresistant S. aureus (MRSA)were tested. These were clinical isolates and so represented opportunistic pathogens. In addition about 20 strains of Bacillus were studied (Table 1) .
Growth Conditions and Antibiotic Challenge
Bacillus strains were grown overnight in 5 ml of Luria Bertani medium (LB: 1 % Tryptone, 0.5% Yeast Extract, 0.5% NaCl), then 100/xl was pipetted into 10ml offresh LB. After shaking for 90 minutes, rifampicin was added (from a 100 x stock in methanol) to a final concentration of 20 /ig/ml. 37°C was the incubation temperature for all * Permanent address: Genetics Department, University of the Witwatersrand, Jan Smuts Aven., Johannesburg 2050, South Africa. organisms except B. stearothermophilus, which was grown at 55°C. Aliquots removed at intervals were assayed for residual antibiotic concentration based on zones of inhibition on a lawn of B. subtilis PCI 219 in Fig. 1 comparison with a dilution series of known rifampicin concentrations. For other organisms, between 10 and 30/ig/ml was used in challenge experiments, and incubation at 37°C was for 72hours. For all organisms, rifampicin and its inactivated derivatives were extracted from 2ml of culture using 1 ml EtOAc after adjusting to pH 2 with 1 drop 6n HC1. 0.5ml ofEtOAc extract was vacuum dried then dissolved in 20/A acetone. 5/il was spotted on TLCplates. Some Bacillus strains decolorized rifampicin and concomitantly the antibiotic activity disappeared.
Therefore, for these strains, the term "decolorization" was used.
Mutagenesis
Mutants of strain 1A3 were obtained after 15 minutes exposure of washed cells to 100/ig/ml TV-methyl-TV'-nitro-7V-nitrosoguanidine in Tris-maleate buffer, pH 4.8 at 37°C. After outgrowth, clones were screened on plates for susceptibility to 30 ng/ml rifampicin and those which were unable to grow were tested for inactivating ability. Among such mutants, designated as 1A3 iri" was used in the present studies.
Growth Monitoring by an Automatic Growth MeasurementSystem Approximately 104CFU/ml of B. subtilis 1A3 or its iri~mutant were added to duplicate wells (containing 50/il Spizizen medium with 1% casamino acids and 0. 1 %yeast extract) of a microplate containing different concentrations of rifampicin in the same medium.The plate was placed in a Bioscreen C spectrometer (Labsystems, Tokyo, Japan). Growth of cells was monitored by turbidity measurements every 20 minutes. Data were recorded by a computer interfaced with analyzer and growth curves generated for each suspension.
Large-scale Preparation of Inactivation Products
Inactivated rifampicin was obtained after challenge of 1 liter of Bacillus IA3 strain's culture with 100//g/ml antibiotic. After 72 hours incubation at 37°C cells were removed by centrifugation at 6,000 rpm and the supernatant adjusted to pH 2.0 with 2n HC1 then extracted three times with an equal volume of ethyl acetate. The extracted layer was washed with distilled water. The EtOAc layer was dehydrated with Na2SO4and concentrated in vacuo to dryness. Dried material was purified by silica gel column chromatography using Wakogel C-200 (Wako Pure Chemicals, Japan) and a mixture of CHC13and MeOH(95 : 5) as solvent. Preparative silica gel TLC was made using CHC13-MeOH,4: 1 for RIP- 
Results

Inactivation Experiments
Clinical isolates of Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus (see Materials and Methods) were tested for inactivation activity against rifampicin. Antibiotic potency, as determined by zones of inhibition on a lawn of assay organism, was not affected by any of the strains of these bacteria which were tested. TLCsof rifampicin obtained after exposure to these isolates did not reveal the presence of any modified compound. Therefore none of these strains could be shown to inactivate rifampicin. In contrast, most strains of Bacillus which we tested were able to inactivate this antibiotic. Low concentrations (<2jug/ml) were completely inactivated in <4 hours; by selection of rifampicin resistant strains to eliminate inhibitory effects of this compound it was found that 100/ig/ml was inactivated in 8~10hours. Representative inactivation curves for B. subtilis strains 1A3 and PCI 219 are shown in Fig. 2A . Also included is a result with a mutant of 1A3 that had been selected on the basis of loss of rifampicin inactivating ability 817 (termed iri ). The parental strain completely inactivated 20jUg/ml in about 5hours whereas the mutant did not detectably lower this concentration of antibiotic in 12hours ( Fig. 2A) . As shown in Table 1 , the rifampicin MICof the mutant was four fold lower due to the absence of this ability. We monitored growth of 1A3 and its mutant in the presence of rifampicin (0.015 fig/ml and 0.030 /ig/ml) using the Bioscreen automatic growth measurement system. The mutant showed a lag of about 26 to 28hours in comparison with the parent (Fig. 3) .
Cultures of about eighteen other Bacillus species were examined and eleven of these could inactivate rifampicin at rates similar to B. subtilis (e.g. B. cereus and B. pumilus, Fig. 2B ). The remainder showed no evidence of inactivation even after prolonged incubation (see e.g. B. globigii, Fig. 2B ). We measured MIC for these organisms and found that except for the thermophile B. stearothermophilus all strains with values of 0.025/jg/ml or below were unable to inactivate rifampicin whilst except for B. sphaericus all organisms with values above 0.025 jug/ml did inactivate ( Table 1) .
Nature of Inactivation TLCs of extracts from rifampicin-challenged
Bacillus cultures revealed three patterns of behavior (Fig. 4) . For the seven species which did not inactivate the antibiotic there was no change in this compound.The same was true for the non-inactivating mutant of B. subtilis 1A3. Most other B. subtilis strains modified the antibiotic such that Rf was close to zero, similar to what was seen with phosphorylative inactivation by Nocardia otitidis- -åºshows origin of sample applied. caviarum8). An exception was strain PCI 219, which decolorized the antibiotic in a fashion resembling that seen with many Rhodococcus strains8'10'1X) as well as N. asteroides8).
For Bacillus species apart from B. subtilis, eight displayed the phosphorylative pattern of inactivation and four the decolorization ( Table 1 ).
The nature of the rifampicin modification was deter- (Fig. 1 ).
Discussion
Our previous work has demonstrated that nocardioform bacteria of the genera Nocardia, Rhodococcus, and 
